Evidence map›Paper›PMID 38661372›Full record

Observational studyBlood advances2024

Trends in volumes and survival after hematopoietic cell transplantation in racial/ethnic minorities.

Nandita Khera, Sikander Ailawadhi, Ruta Brazauskas, Jinalben Patel, Benjamin Jacobs, Celalettin Ustun, Karen Ballen, Muhammad Bilal Abid, Miguel Angel Diaz Perez, A Samer Al-Homsi and 33 more

Open access · goldAbstract readObservational Study
In one paragraph

Observational study in Blood advances, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed, 1 pooled it
8.6field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 1 synthesis or guideline pooled it, 19 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

43 authors at 20 institutions in 6 countries.

Nandita KheraDepartment of Hematology/Oncology, Mayo Clinic, Phoenix, AZ.
Sikander AilawadhiDivision of Hematology-Oncology, Mayo Clinic Florida, Jacksonville, FL.
Ruta BrazauskasDivision of Biostatistics, Institute for Health and Equity, Medical College of Wisconsin, Milwaukee, WI.
Jinalben PatelCenter for International Blood and Marrow Transplant Research, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI.ORCID 0009-0002-9301-9941
Benjamin JacobsCenter for International Blood and Marrow Transplant Research, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI.
Celalettin UstunDivision of Hematology, Oncology, and Cell Therapy, Rush University, Chicago, IL.ORCID 0000-0001-6896-6213
Karen BallenDivision of Hematology/Oncology, University of Virginia Health System, Charlottesville, VA.
Muhammad Bilal AbidDivisions of Hematology/Oncology & Infectious Diseases, BMT & Cellular Therapy Program, Medical College of Wisconsin, Milwaukee, WI.ORCID 0000-0002-1128-0445
Miguel Angel Diaz PerezDepartment of Hematology/Oncology, Hospital Infantil Universitario Niño Jesus, Madrid, Spain.ORCID 0000-0001-5286-1329
A Samer Al-HomsiNew York University Grossman School of Medicine, Langone Health, New York, NY.
Hasan HashemDivision of Pediatric Hematology/Oncology and Bone marrow Transplantation, King Hussein Cancer Center, Amman, Jordan.ORCID 0000-0002-4681-4726
Sanghee HongDivision of Hematologic Malignancies and Cellular Therapy, Department of Medicine, Duke University School of Medicine, Durham, NC.
Reinhold MunkerMarkey Cancer Center, University of Kentucky, Lexington, KY.
Raquel M SchearsUniversity of Central Florida, Department of Emergency Medicine, Orlando, FL.
Hillard M LazarusUniversity Hospitals Cleveland Medical Center, Case Western Reserve University, Cleveland, OH.
Stefan CiureaHematopoietic Stem Cell Transplantation and Cellular Therapy Program, University of California, Irvine, Orange, CA.ORCID 0000-0001-8597-3271
Sherif M BadawyDepartment of Pediatrics, Northwestern University Feinberg School of Medicine, Chicago, IL.ORCID 0000-0002-4739-265X
Bipin N SavaniDivision of Hematology/Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN.ORCID 0000-0002-3304-9965
Baldeep WirkBone Marrow Transplant Program, Penn State Cancer Institute, Hershey, PA.
C Fred LeMaistreSarah Cannon, Nashville, TN.ORCID 0000-0003-2462-0186
Neel S BhattDivision of Hematology/Oncology and Bone Marrow Transplant, Department of Pediatrics, University of Washington School of Medicine, Seattle, WA.ORCID 0000-0003-2033-1125
Amer BeitinjanehDivision of Transplantation and Cellular Therapy, University of Miami Hospital and Clinics, Sylvester Comprehensive Cancer Center, Miami, FL.
Mahmoud AljurfOncology Center, King Faisal Specialist Hospital Center & Research, Riyadh, Saudi Arabia.
Akshay SharmaDepartment of Bone Marrow Transplantation and Cellular Therapy, St. Jude Children's Research Hospital, Memphis, TN.ORCID 0000-0003-3281-2081
Jan CernyDivision of Hematology/Oncology, Department of Medicine, University of Massachusetts Chan Medical School and Medical Center, Worcester, MA.ORCID 0000-0002-6602-5505
Jennifer M KnightDivision of Hematology/Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI.ORCID 0000-0002-9140-3109
Amar H KelkarDana-Farber Cancer Institute, Harvard Medical School, Boston, MA.ORCID 0000-0001-7627-8509
Jean A YaredTransplantation & Cellular Therapy Program, Division of Hematology/Oncology, Department of Medicine, Greenebaum Comprehensive Cancer Center, University of Maryland, Baltimore, Baltimore, MD.
Tamila Kindwall-KellerMetroHealth System, Case Western Reserve University, Cleveland, OH.
Lena E WinestoneDivision of Allergy, Immunology, and Blood & Marrow Transplant, University of California, San Francisco Benioff Children's Hospitals, San Francisco, CA.ORCID 0000-0001-9982-1594
Amir SteinbergWestchester Medical Center, Valhalla, NY.
Staci D ArnoldAflac Cancer and Blood Disorder Center, Children's Healthcare of Atlanta, Emory University, Atlanta, GA.ORCID 0000-0001-6053-8521
Sachiko SeoDepartment of Hematology and Oncology, Dokkyo Medical University, Tochigi, Japan.ORCID 0000-0002-4308-2152
Jaime M PreusslerCenter for International Blood and Marrow Transplant Research, National Marrow Donor Program/Be The Match, Minneapolis, MN.ORCID 0000-0001-7047-5720
Nasheed M HossainDivisions of Hematology/Oncology, Department of Medicine, Cell Therapy and Transplantation Program, University of Pennsylvania, Perelman School of Medicine, Philadelphia, PA.ORCID 0000-0002-3278-655X
Warren B FingrutHarvard T.H. Chan School of Public Health, Boston, MA.ORCID 0000-0002-5017-1583
Vaibhav AgrawalDivision of Leukemia, Department of Hematology & Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA.
Shahrukh HashmiDepartment of Medicine, Sheikh Shakhbout Medical City, Abu Dhabi, UAE.ORCID 0000-0002-8914-7927
Leslie E LehmannDana Farber Boston Children's Cancer and Blood Disorder Center, Boston, MA.
William A WoodDivision of Hematology, Department of Medicine, The University of North Carolina at Chapel Hill, Chapel Hill, NC.
Hemalatha G RangarajanDepartment of Pediatric Hematology, Oncology, Blood and Marrow Transplantation, Nationwide Children's Hospital, Columbus, OH.ORCID 0000-0003-3371-2920
Wael SaberCenter for International Blood and Marrow Transplant Research, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI.
Theresa HahnDepartment of Cancer Prevention & Control, Roswell Park Comprehensive Cancer Center, Buffalo, NY.
Medical College of Wisconsin · USDana-Farber Cancer Institute · USCity Of Hope National Medical Center · USDokkyo Medical University · JPDuke University · USEmory University · USHospital Infantil Universitario Niño Jesús · ESKhalifa University of Science and Technology · AEKing Faisal Specialist Hospital & Research Centre · SAKing Hussein Cancer Center · JOMayo Clinic in Florida · USMemorial Sloan Kettering Cancer Center · USMetroHealth · USNational Marrow Donor Program · USNationwide Children's Hospital · USNew York University · USNorthwestern University · USRoswell Park Comprehensive Cancer Center · USRush University · USSarah Cannon · US

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4M
Data Resource for Analyzing Blood &Marrow TransplantsU24CA076518 · NCI · MEDICAL COLLEGE OF WISCONSIN · PI Amy M Moskop, Bronwen Shaw · 1998 to 2026
$105.2M
NTP INFORMATION SYSTEMS SUPPORT27305C0011 · NIEHS · Z-TECH CORPORATION · 2007 to 2009
$4.3M
PROVIDE RABBITS, RATS, MICE, HAMSTERS, GERBILS, GUINEA PIGS27307C0011 · NIEHS · PI BOLEN, WAYNE · 2007 to 2007
$500k
NCI NIH HHS P30 CA008748NCI NIH HHS U24 CA076518NIEHS NIH HHS 27305C0011NIEHS NIH HHS 27307C0011NIEHS NIH HHS 27398C0011
6 · The paper itself

Abstract

abstractThere has been an increase in volume as well as an improvement in overall survival (OS) after hematopoietic cell transplantation (HCT) for hematologic disorders. It is unknown if these changes have affected racial/ethnic minorities equally. In this observational study from the Center for International Blood and Marrow Transplant Research of 79 904 autologous (auto) and 65 662 allogeneic (allo) HCTs, we examined the volume and rates of change of autoHCT and alloHCT over time and trends in OS in 4 racial/ethnic groups: non-Hispanic Whites (NHWs), non-Hispanic African Americans (NHAAs), and Hispanics across 5 2-year cohorts from 2009 to 2018. Rates of change were compared using Poisson model. Adjusted and unadjusted Cox proportional hazards models examined trends in mortality in the 4 racial/ethnic groups over 5 study time periods. The rates of increase in volume were significantly higher for Hispanics and NHAAs vs NHW for both autoHCT and alloHCT. Adjusted overall mortality after autoHCT was comparable across all racial/ethnic groups. NHAA adults (hazard ratio [HR] 1.13; 95% confidence interval [CI] 1.04-1.22; P = .004) and pediatric patients (HR 1.62; 95% CI 1.3-2.03; P < .001) had a higher risk of mortality after alloHCT than NHWs. Improvement in OS over time was seen in all 4 groups after both autoHCT and alloHCT. Our study shows the rate of change for the use of autoHCT and alloHCT is higher in NHAAs and Hispanics than in NHWs. Survival after autoHCT and alloHCT improved over time; however, NHAAs have worse OS after alloHCT, which has persisted. Continued efforts are needed to mitigate disparities for patients requiring alloHCT.

Indexed as

Hematopoietic Stem Cell TransplantationAdolescentAdultAgedChildChild, PreschoolEthnic and Racial MinoritiesFemaleHumansMaleMiddle AgedYoung Adult

Identifiers

PMID38661372
PMCPMC11260842
OpenAlexW4395465396

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.